297 related articles for article (PubMed ID: 35178386)
41. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
Yin T; Zhao L; Yao S
BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
[TBL] [Abstract][Full Text] [Related]
42. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
43. N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma.
Wang G; Zeng D; Sweren E; Miao Y; Chen R; Chen J; Wang J; Liao W; Hu Z; Kang S; Garza LA
J Invest Dermatol; 2023 Aug; 143(8):1579-1590.e5. PubMed ID: 36842525
[TBL] [Abstract][Full Text] [Related]
44. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
[TBL] [Abstract][Full Text] [Related]
45. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract][Full Text] [Related]
46. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma.
Xu W; Li H; Hameed Y; Abdel-Maksoud MA; Almutairi SM; Mubarak A; Aufy M; Alturaiki W; Alshalani AJ; Mahmoud AM; Li C
Oncol Res; 2023; 31(5):819-831. PubMed ID: 37547754
[TBL] [Abstract][Full Text] [Related]
47. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia.
Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
Front Immunol; 2021; 12():789914. PubMed ID: 34887874
[TBL] [Abstract][Full Text] [Related]
48. m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia.
Xu ZJ; Wen XM; Zhang YC; Jin Y; Ma JC; Gu Y; Chen XY; Xia PH; Qian W; Lin J; Qian J
Front Genet; 2022; 13():948079. PubMed ID: 36035161
[TBL] [Abstract][Full Text] [Related]
49. Integrated Analyses of m
Cao Q; Chen Y
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232485
[TBL] [Abstract][Full Text] [Related]
50. Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.
Yang S; Li K; Zhang J; Liu J; Liu L; Tan Y; Xu C
Exp Biol Med (Maywood); 2023 Dec; 248(23):2273-2288. PubMed ID: 38166412
[TBL] [Abstract][Full Text] [Related]
51. RNA M6A modification shaping cutaneous melanoma tumor microenvironment and predicting immunotherapy response.
Wu Y; He H; Zheng K; Qin Z; Cai N; Zuo S; Zhu X
Pigment Cell Melanoma Res; 2024 Jul; 37(4):496-509. PubMed ID: 38624045
[TBL] [Abstract][Full Text] [Related]
52. Integrating machine learning and bioinformatics analysis to m6A regulator-mediated methylation modification models for predicting glioblastoma patients' prognosis and immunotherapy response.
Li C; Liu W; Liu C; Luo Q; Luo K; Wei C; Li X; Qin J; Zheng C; Lan C; Wei S; Tan R; Chen J; Chen Y; Huang H; Zhang G; Huang H; Wang X
Aging (Albany NY); 2023 May; 15(10):4051-4070. PubMed ID: 37244287
[TBL] [Abstract][Full Text] [Related]
53. Integrated Analyses of m6A Regulator-Based Signature on Its Clinical Application and Immunogenomic Landscape in Stomach Adenocarcinoma.
Zhang L; Zhang Q; Huang Z; Zhu M; Wang T; Zhu W; Wang X; Zhou X
Biomed Res Int; 2022; 2022():2053719. PubMed ID: 36193316
[TBL] [Abstract][Full Text] [Related]
54. m
Sun M; Xie M; Zhang T; Wang Y; Huang W; Xia L
Front Immunol; 2021; 12():739768. PubMed ID: 34616403
[TBL] [Abstract][Full Text] [Related]
55. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma.
Li H; Hu J; Yu A; Othmane B; Guo T; Liu J; Cheng C; Chen J; Zu X
Front Oncol; 2021; 11():642159. PubMed ID: 33816290
[TBL] [Abstract][Full Text] [Related]
56. RNA N6-Methyladenosine Regulators Contribute to Tumor Immune Microenvironment and Have Clinical Prognostic Impact in Breast Cancer.
Mu LX; Shao YC; Wei L; Chen FF; Zhang JW
Front Genet; 2021; 12():650499. PubMed ID: 35095993
[No Abstract] [Full Text] [Related]
57. Novel insight of N
Wang K; Kan Q; Ye Y; Qiu J; Huang L; Wu R; Yao C
Front Genet; 2022; 13():1055396. PubMed ID: 36482903
[No Abstract] [Full Text] [Related]
58. Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas.
Cai Z; Zhang J; Liu Z; Su J; Xu J; Li Z; Meng H; Zhang H; Huang M; Zhao D; Duan C; He X
Ann Transl Med; 2021 Aug; 9(15):1241. PubMed ID: 34532378
[TBL] [Abstract][Full Text] [Related]
59. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
60. Identification of the expression patterns and potential prognostic role of m6A-RNA methylation regulators in Wilms Tumor.
Jia C; Gao H; Ma W; Liu X; Chang M; Sun F
BMC Med Genomics; 2023 Sep; 16(1):222. PubMed ID: 37735424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
